Presentations (slides, Video) and Abstract are available to GBCC Sign-up members.
You can access after log-in.
Scientific Program
Program at a Glance
Scientific Program
Invited Speakers
  • Symposium 1: 
    States-of-Art: Personalized Surgery in Breast Cancer68
  • Venue:  RM 1 (Vista 1+2)
  • Omission of Sentinel Lymph Node Biopsy in Early Breast Cancer
     (, )
  • Tailored Axillary Surgery in Axillary Node-Positive Early Breast Cancer
    Andrea Barrio
     (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Omission of Breast Surgery in Patients with Exceptional Response to Neoadjuvant Systemic Therapy
    Tomomi Fujisawa
     (Gunma Prefectural Cancer Center, Japan)
  • Panel Discussion 1: 
    Optimizing Treatment Sequence After CDK4/6 Inhibitors71
  • Venue:  RM 2 (Grand 1)
  • Resistance Mechanism of CDK4/6 Inhibitor: Primary or Acquired
     (, )
  • What Is the Optimal Treatment Strategy After the First Line CDK4/6 Inhibitor?
    Yoon-Sim Yap
     (National Cancer Centre Singapore, Singapore)
  • Antibody Drug Conjugate for HR+HER2- MBC
     (, )
  • Symposium 2: 
    Artificial Intelligence: Past, Present and Future64
  • Venue:  RM 3 (Walker Hall 1)
  • Practical Considerations and the Implementation of AI Tools for Breast Cancer Risk Prediction
    Thijs Kooi
     (Lunit Inc., Korea)
  • Artificial Intelligence in Real-World Experiences: Perspectives of Radiologists
    Won Hwa Kim
     (Kyungpook National Univ. Chilgok Hospital, Korea)
  • Artificial Intelligence in Breast Pathology: Current Landscape and Future Prospects
    Miseon Lee
     (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • IERBS 2024 1: 
    Current Status and Issues for Robotic and Endoscopic NSM88
  • Venue:  RM 4 (Walker Hall 2)
  • Patients Selection of Robotic and Endoscopic NSM for Beginners
    Sae Byul Lee
     (Asan Medical Center, Korea)
  • Ongoing Studies of Robotic or Endoscopic NSM
    Chi Wei Mok
     (Changi General Hospital, Singhealth Duke-NUS Breast Centre, Singapore)
  • Current Application of Robotic and Endoscopic NSM for High Risk of Breast Cancer Patients
    Deborah Farr
     (UT Southwestern Medical Center, U.S.A.)
  • GBCC-SSO Joint Session: 
    GBCC-SSO Joint Session104
  • Venue:  RM 5 (Art Hall)
  • Oral Presentation 1: 
    Oral Presentation 1116
  • Venue:  RM 6 (Grand 4)
  • Symposium 3: 
    The New Frontier of Endocrine Treatment for Breast Cancer65
  • Venue:  RM 1 (Vista 1+2)
  • Oral SERDs and Novel Endocrine Therapy Agents
    Gun Min Kim
     (Yonsei Cancer Center, Korea)
  • Targeting PI3K-mTOR-AKT Pathway in HR+ Breast Cancer
     (, )
  • New Targets in Hormone Receptor Positive Breast Cancer
     (, )
  • Panel Discussion 2: 
    Surgical Controversies Before and After Neoadjuvant Chemotherapy in the Era of Targeted Therapy72
  • Venue:  RM 2 (Grand 1)
  • Need to Complete Removal of Residual Microcalcifications? - In Case Highly Suggestive of Clinical pCR in MRI and with Residual Diffuse Microcalcification in Mammogram
    Tari King
     (Dana-Farber Brigham Cancer Center, U.S.A.)
  • Inflammatory Breast Cancer Following Good Response to Neoadjuvant Therapy: No Longer an Absolute Contraindication for Breast Conservation or Skin-Sparing Mastectomy? - Does Initial Extent or Severity Matter?
    Stephanie M. Wong
     (Jewish General Hospital, Canada)
  • Young Age Breast Cancer with cT1-3Nx, Low Grade, ER+ Tumor - Upfront Surgery or Neoadjuvant Chemotherapy?
     (, )
  • Education Session 1: 
    What Radiologists Should Know for Optimal Interpretation in Patients Treated with NAC77
  • Venue:  RM 3 (Walker Hall 1)
  • Synergy from Surgical Viewpoint: A Holistic Imaging Interpretation with Intraoperative Experience
    Joon Jeong
     (Gangnam Severance Hospital, Korea)
  • Synergy from Oncological Viewpoint: Exploring Current Trends and Principles of Chemotherapy
    Jae-Joon Kim
     (Pusan National Univ. Yangsan Hospital, Korea)
  • Contemporary Imaging Insights and Interpretation Considerations for Patients Undergoing Neoadjuvant Systemic Therapy
    Kazunori Kubota
     (Dokkyo Medical Univ. Saitama Medical Center, Japan)
  • IERBS 2024 2: 
    Initiation and Troubleshooting of Robotic and Endoscopic NSM89
  • Venue:  RM 4 (Walker Hall 2)
  • Implication of Dry and Cadevaric Skill Labs for Robotic and Endoscopic NSM
    Jeffrey Johnson
     (Mayo Clinic, U.S.A.)
  • Robotic and Endoscopic NSM in Large & Ptotic Patients
    Wen-Ling Kuo
     (Chang Gung Memorial Hospital, Taiwan)
  • Managing Postop-Complications of Robotic and Endoscopic NSM Compared to Open NSM
    Eisuke Fukuma
     (Kameda Medical Center, Japan)
  • GBCC-JBCS Joint Session: 
    GBCC-JBCS Joint Session105
  • Venue:  RM 5 (Art Hall)
  • Oral Presentation 2: 
    Oral Presentation 2117
  • Venue:  RM 6 (Grand 4)
  • Plenary Lecture 1: 
    Plenary Lecture 1121
  • Venue:  RM 1 (Vista 1+2)

  • Dennis Slamon
     (Univ. of California, Los Angeles, U.S.A.)
  • Satellite Symposium 1: 
    Satellite Symposium 1111
  • Venue:  RM 1 (Vista 1+2)
  • Plenary Lecture 2: 
    Plenary Lecture 2122
  • Venue:  RM 1 (Vista 1+2)

  • Timothy Whelan
     (McMaster Univ., Canada)
  • IERBS 2024 3: 
    Debate: Is Robot Assisted NSM Role Outside of Clinical Trials?90
  • Venue:  RM 4 (Walker Hall 2)
  • Pros
    Antonio Toesca
     (Candiolo Cancer Institute - IRCCS, Italy)
  • Cons
    Andrea Barrio
     (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Panel Discussion 3: 
    Beyond Borders: Breaking Barriers of Subtypes73
  • Venue:  RM 2 (Grand 1)
  • Tumor Agnostic Trials Across Subtypes in Metastatic Breast Cancer
    Giuseppe Curigliano
     (European Institute of Oncology and Univ. of Milano, Italy)
  • Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer
    Janice Tsang
     (The Univ. of Hong Kong, Hong Kong)
  • Identifying Biological Entity That Is Sensitive to Immune Checkpoint Inhibitors
    Hee Kyung Ahn
     (Gachon Univ. Gil Medical Center, Korea)
  • Education Session 2: 
    Biomarkers Guided Treatment in ER+HER2- Breast Cancer78
  • Venue:  RM 3 (Walker Hall 1)
  • Liquid Biopsies Guided Treatment in ER+HER2- Breast Cancer
    Sarat Chandarlapaty
     (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Multigene Assays Based Decision for Extended Endocrine Therapy
    Masakazu Toi
     (Kyoto Univ. Hospital, Japan)
  • Biomarkers for Neoadjuvant Endocrine Therapy
    Shigehira Saji
     (Fukushima Medical Univ., Japan)
  • IERBS 2024 4: 
    PS Session91
  • Venue:  RM 4 (Walker Hall 2)
  • Robot-Assisted Breast Reconstruction
    Benjamin Sarfati
     (Institut Gustave Roussy, France)
  • Robot-Assisted Breast Reconstruction
    Dong-Won Lee
     (Yonsei Univ., Korea)
  • Autologous Breast Reconstruction - Japanese Trend and Our Strategy
    Hiroki Mori
     (Tokyo Medical and Dental Univ., Japan)
  • GBCC-TBCS Joint Session: 
    Asian Premenopausal Women with Breast Cancer106
  • Venue:  RM 5 (Art Hall)
  • Oral Presentation 3: 
    Oral Presentation 3118
  • Venue:  RM 6 (Grand 4)
  • Panel Discussion 4: 
    Subtype-Based Optimization of Locoregional Treatments for Small Tumors74
  • Venue:  RM 2 (Grand 1)
  • Treatment Approach in Small HER2+ or TNBC: Upfront Surgery vs Neoadjuvant Chemotherapy?
    Marios Tasoulis
     (The Royal Marsden Hospital, United Kingdom)
  • Small Luminal a Breast Cancer in Postmenopausal Women: SLNB Omission vs RT Omission?
     (, )
  • Small Luminal a Breast Cancer in Postmenopausal Women: SLNB Omission vs RT Omission?
     (, )
  • Education Session 3: 
    The Power of Genomics for Breast Cancer79
  • Venue:  RM 3 (Walker Hall 1)
  • Technology of Genomic Profiling in Breast Cancer: How to Interpret Genomic Testing
    In Hye Song
     (Asan Medical Center, Univ. of Ulsan College of Medicine, Korea)
  • Tumor vs cfDNA Analysis in Breast Cancer
    Pedram Razavi
     (Memorial Sloan Kettering Cancer Center, U.S.A.)
  • Actionable Mutations in Breast Cancer: Molecular Insights and Therapeutic Approaches
    Min Hwan Kim
     (Yonsei Univ. College of Medicine, Korea)
  • IERBS 2024 5: 
    Consensus Meeting: Voting Session92
  • Venue:  RM 4 (Walker Hall 2)
  • Introduction Consensus Meeting of IERBS & Summary of Previous Consensus Meeting of IERBS
    Hung-Wen Lai
     (Changhua Christian Hospital, Taiwan)
  • GBCC-BIG25: 
  • Venue:  RM 5 (Art Hall)
  • Oral Presentation 4: 
    Oral Presentation 4119
  • Venue:  RM 6 (Grand 4)

Global Breast Cancer Conference Secretariat

Partner I INTERCOM Convention Services, Inc. (Core PCO)